← BackSotera Health Co · Misc Health & Allied Services, NECSHC
Low riskNext report: In 6 days (est.)
The short versionA profitable company with steady sales. Institutions are adding.
Going well
- Profitable
- Brings in more cash than it spends
Money moves
- No insider buying or selling in the last 30 days
- Institutions added 7.3% to their holdings in the quarter ending June 2026 (217 bought, 98 sold)
- Held by Ray Dalio (Bridgewater)
Facts from SEC filings, not a recommendation.
What the price means
Price as of Oct 26
$18.39+1.6% that day
- Company value
- $5.2B
- Share price times all shares
- Price vs profit (P/E)
- 32.3x
- You pay about $32 for each $1 of yearly profit
- Price vs sales
- 4.3x
- Company value is 4.3 times a year of sales
- Cash vs value
- 7%
- Cash as a share of company value
- Debt vs value
- 41%
- Debt as a share of company value
From SHC's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.
The business over time
Last 12 quarters, from SEC filings
Sales, Jun '26$321.4M+9.2% vs a year earlier
Sep '23Tap a barJun '26
Last 12 months: $1.2B, up 8.1% from the 12 months before. Over 5 years, sales grew about 7.3% a year.
Business quality
The checklist Warren Buffett-style investors use. Annual numbers for 2025.- PassReturn on equity 15%+Earns a lot on the money owners have in the business.15.4%
- MissDebt under half of equityNot relying on borrowed money.3.53x equity
- MissNet margin 10%+Keeps at least 10 cents of profit from each dollar of sales.6.7%
- MissProfitable every yearSteady profits, not one good year.4 of 7 years
- PassFree cash flow positiveBrings in more cash than it spends to run and grow.$149.2M
- MissShare count not growingNot diluting owners. Falling means buybacks.+2.3% in 3 years
- PassGross margin 40%+Pricing power: sells for well above what it costs to make.55.5%
- Revenue
- $1.2B
- +5.7% vs prior year
- 5-year growth
- +7.3%/yr
- revenue, per year
- Total debt
- $2.1B
- 3.53x equity
- Current ratio
- 2.46x
- short-term assets / bills due
From annual reports filed with the SEC. A checklist is a starting point for research, not a verdict.
Latest quarter
Quarter ended Jun 30, 2026- Revenue
- $321.4M
- +9.2% YoY
- EPS
- $0.19
- vs $0.03
- Gross margin
- 55.4%
- -1.2 pts
- Free cash flow
- $42.0M
- Share count
- +0.8%
- vs a year ago
Insider rating
Last 90 days
No open-market insider buys or sells in the last 90 days.
Weekly insider trendNo trades to chart yet.
Filing buzz
Last 7 days vs normal
0/ 100
- This week
- 0
- Normal week
- 0.9
- vs normal
- 0.0x
SEC filings of any kind. 50 means a normal week.
Institutional ownership
▲Accumulating+7.3%Institutions added 7.3% to their holdings. 217 bought, 98 sold. 3 quarters of net buying in a row.
Shares held by institutions294.7M
Sep '24Jun '26
Share count growthYearly rate, last 3 years
+0.3%Cash runwayAt last year's cash burn
Cash flow positiveDebt to equityLatest balance sheet: debt compared with what owners have
3.2x · $2.1B debtShares outstandingLatest reported
285MNext reportIn 6 days (est.)Estimated from the same quarter last year
- Results filedAug 6
- Results filedMay 5
- Results filedFeb 24
- Results filedJan 12
- Results filedNov 4, 2025
Insider trades
Open-market buys and sells, last 90 days
No open-market buys or sells in 90 days. Grants and option exercises are left out.
"Owns after" is the insider's holding right after the trade. Pre-planned (10b5-1) sales are set up months ahead, a weaker signal.
Latest filings
Straight from SEC EDGAR
5%+ holder update (passive)Oct 9 · Form SCHEDULE 13G/A ↗SoldMichael B. Jr. PetrasExecutive Chairman, Director
1,144,515 shares at $18.50 · $21.2M
- -22% of holdings
- Now owns 3,969,393 shares
- Not a pre-planned sale
- Held by Grantor Trust
- 2 transactions
- Filed 2 days after trade
Planned insider saleAug 17 · Form 144 ↗Leadership changeAug 14 · Form 8-K ↗5%+ holder update (passive)Aug 14 · Form SCHEDULE 13G/A ↗5%+ holder update (passive)Aug 14 · Form SCHEDULE 13G/A ↗SoldMichael P RutzPresident of Sterigenics
150,000 shares at $18.84 · $2.8M
- -31% of holdings
- Now owns 334,279 shares
- Not a pre-planned sale
- Filed 4 days after trade
Planned insider saleAug 7 · Form 144 ↗Shares withheld for taxesJonathan M. LyonsSr. Vice President, CFO
11,316 shares at $17.98 · $203K
- -5% of holdings
- Now owns 217,304 shares
- Filed 2 days after trade
Earnings resultsAug 6 · Form 8-K ↗Quarterly reportAug 6 · Form 10-Q ↗5%+ holder update (passive)Jul 30 · Form SCHEDULE 13G/A ↗SDMay 29 · Form SD ↗Stock awardDavid E. WheadonDirector
14,970 shares
- +20% of holdings
- Now owns 89,882 shares
- Filed 5 days after trade
Stock awardChristopher Simon,Director
14,970 shares
- +78% of holdings
- Now owns 34,102 shares
- Filed 5 days after trade